MDS Nordion to Supply Cardiac Imaging Pharmaceutical for Molecular Insight Pharmaceuticals, Inc.
16 Febbraio 2006 - 2:00PM
PR Newswire (US)
OTTAWA, Feb. 16 /PRNewswire-FirstCall/ -- MDS Nordion, a world
leader in nuclear medicine, and Molecular Insight Pharmaceuticals,
Inc. (MIP) have signed a six-year renewable contract to manufacture
and supply Zemiva(TM), a molecular imaging pharmaceutical being
developed for cardiac ischemia, or insufficient blood flow to the
heart. Zemiva(TM), currently in clinical trials, is targeted for
the emergency department setting. "MDS Nordion is recognized by
pharmaceutical and biotechnology companies worldwide for a suite of
unique drug development services, which span from the discovery of
new radiopharmaceuticals to the manufacture and reliable commercial
supply of products used in the patient care setting," said Steve
West, President of MDS Nordion. "This contract will enable MDS
Nordion to build upon our strong development partnership with
Molecular Insight Pharmaceuticals through the use of our
significant development and manufacturing capabilities to meet the
commercial market needs of Zemiva(TM)." Zemiva(TM) is currently
manufactured at MDS Nordion's facility in Vancouver, Canada. As a
result of the contract, MDS Nordion will expand its Good
Manufacturing Practice (GMP) manufacturing capabilities at this
facility to support the clinical program and commercial supply of
Zemiva(TM). Zemiva(TM)'s first indication is expected to be for the
rapid diagnosis of cardiac ischemia in a hospital's emergency
department. Data suggests that Zemiva(TM) administered to patients
at rest can detect ischemia through imaging patients up to 30 hours
after a cardiac event has occurred - potentially enabling the
widespread use of imaging in the emergency department for more
rapid diagnosis. Zemiva(TM) allows for the imaging of patients in
acute care settings and has the potential to significantly reduce
the time to treatment, thereby limiting damage to the heart tissue
and eliminating unnecessary hospitalizations. It is estimated that
five to eight million patients in the United States annually
require determination of whether their chest pain is caused by
insufficient blood flow to the heart or heart attack. MDS Nordion
has 60 years of experience in offering consistent product quality,
flexible product options, responsive customer service and strong
technical and scientific expertise to its customers. MDS Nordion's
GMP-compliant facilities located in Ottawa and Vancouver, Canada,
and Fleurus, Belgium, accommodate a variety of development,
manufacturing and supply requirements. About MDS Nordion MDS
Nordion (http://www.mds.nordion.com/) is a world leader in
radioisotopes, radiation and related technologies. MDS Nordion is
part of MDS Inc. (TSX:MDS; NYSE:MDZ). MDS Inc. has more than 8,800
highly skilled people in 28 countries. We provide a diverse range
of superior products and services to increase our customers' speed,
precision and productivity in the drug development and disease
diagnosis processes. We are a global, values-driven health and life
sciences company, recognized for our reliability and collaborative
relationships as we help create better outcomes in the treatment of
disease. Find out more at http://www.mdsintl.com/ or by calling
1-888-MDS-7222, 24 hours a day. DATASOURCE: MDS Nordion CONTACT:
Shelley Maclean, External Communications, MDS Nordion, Tel: (613)
592-3400 ext. 2414, E-mail:
Copyright